GlaxoSmithKline Pakistan Limited (PSX:GLAXO)

Market Cap	141.55B
Revenue (ttm)	61.19B
Net Income (ttm)	6.54B
Shares Out	318.47M
EPS (ttm)	20.52
PE Ratio	21.66
Forward PE	n/a
Dividend	10.00 (2.25%)
Ex-Dividend Date	Apr 18, 2025

Volume	509,583
Average Volume	847,825
Open	449.98
Previous Close	455.26
Day's Range	436.00 - 452.00
52-Week Range	96.00 - 481.00
Beta	0.33
RSI	55.35
Earnings Date	Apr 28, 2025

About GlaxoSmithKline Pakistan

GlaxoSmithKline Pakistan Limited operates as a biopharma company in Pakistan. It deals in anti-infective, dermatology, respiratory, immunology, oncology, infectious diseases, HIV, and vaccines therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol, and Cutivate brands. It also exports its products. The company was founded in 2001 and is headquartered in Karachi, Pakistan. GlaxoSmithKline Pakistan Limited is a subsidiary of GSK plc.

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 2001
• Employees: 1,700
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: GLAXO

Financial Performance

In 2024, GlaxoSmithKline Pakistan's revenue was 61.19 billion, an increase of 23.21% compared to the previous year's 49.66 billion. Earnings were 6.54 billion, an increase of 1124.09%.